Clinical Trials · NCT02054897
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 388
- Start date
- Feb 2014
- Locations
- 86 sites, 9 countries
- Primary endpoint
- Change in HbA1c (Glycosylated Haemoglobin)